Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Main finding · SGLT2 inhibitor prescription, adults with diabetes (n = 716,387)Result — go to the resultStandardized mean difference 1.3%Authors' conclusion
In this analysis of U.S. data from 2022 to 2023, SGLT2 inhibitor prescription among people with a Class 1a recommendation is low.
Study context
- Population
- US adults in 28 health systems (Optum Labs Data Warehouse), April 2022–March 2023, stratified by diabetes
- Participants
- 3,189,827 adults
- Exposure
- Class 1a recommendation present vs absent
- Outcome
- SGLT2 inhibitor prescription rate
Methodological details28 US health systems
- 28 US health systems
Main finding
As reported in the abstract
SGLT2 inhibitor prescription, adults with diabetes (n = 716,387)
Standardized mean difference
1.3%
By group
- Adults with diabetes with a Class 1a recommendation
- 63.4%
Observational data: associations, not effects.
Further findings
SGLT2 inhibitor prescription, adults without diabetes with a Class 1a recommendation (n = 2,473,440 without diabetes)
- Adults without diabetes with a Class 1a recommendation
- 6.2%
- Prescription rate among those with Class 1a recommendation
- 3.1% (3.0%-3.2%)
Prescribers
- Internists/family practitioners initiated most commonly with diabetes; specialists most commonly without diabetes
Health-system variation
- No health system had >25% prescription rate among people with a Class 1a recommendation
- Higher rates in systems with more commercial insurance and less Medicare
Original publication
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems. J Am Coll Cardiol. Published 20 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →